Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib +/- Apatinib Maintenance in PARPi-pretreated Ovarian Cancer
NCT06161272Phase 2Not yet recruiting
- Sponsor
- Guangxi Medical University
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib, Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Guangxi Medical University. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
fluzoparibRivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT06161272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161272.